Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Accured Expenses (2021 - 2025)

Abeona Therapeutics (ABEO) has 10 years of Change in Accured Expenses data on record, last reported at -$1.4 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 1625.32% year-over-year to -$1.4 million; the TTM value through Sep 2025 reached $1.6 million, up 52.46%, while the annual FY2024 figure was $1.5 million, 26.16% down from the prior year.
  • Change in Accured Expenses reached -$1.4 million in Q3 2025 per ABEO's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.3 million in Q4 2021 and bottomed at -$4.4 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $11277.8, with a median of $315000.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: surged 554.05% in 2022, then plummeted 169100.0% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $5.3 million in 2021, then crashed by 172.14% to -$3.8 million in 2022, then skyrocketed by 133.55% to $1.3 million in 2023, then soared by 33.46% to $1.7 million in 2024, then tumbled by 179.85% to -$1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$1.4 million in Q3 2025, $1.2 million in Q2 2025, and $112000.0 in Q1 2025.